Search

everythinglearnresearchcommunity

for

Search:↓

LRIG1 is linked to better survival in Merkel cell carcinoma.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

HPV infection is linked to better survival in advanced anal cancer, higher radiation doses improve survival, especially in HPV-negative patients, and prostaglandin E₂ pretreatment can protect mouse hair follicles from radiation damage.

Sorafenib after liver surgery may increase survival for some liver cancer patients.

Removing lymph nodes does not improve survival for advanced ovarian cancer and may cause more complications.

The microenvironment affects the behavior and survival of melanocytes with the GNAQ oncogene in melanoma.

Skin side effects from melanoma immunotherapy are common and may indicate better survival.

The number of new cases of cutaneous B-cell lymphoma has leveled off since the early 2000s, and survival rates have improved since 1973.

Aminopterin was somewhat effective in acute lymphoblastic leukemia in children but did not increase survival time.

WWOX deficiency in mice causes skin and fat tissue problems due to disrupted cell survival signals.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.

Hormone therapy might be a proactive alternative to watchful waiting for early-stage prostate cancer, potentially improving survival without aggressive treatment downsides.

Mesothelioma of the tunica vaginalis testis is rare, often high-grade, and has a median survival of about 24 months.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

High doses of ethynylestradiol in rats caused growth issues, organ changes, and some tumors, but didn't increase overall tumor rates.

Nasolabial skin-fat grafts are good for nasal reconstruction with minimal scarring and no need for bolsters, but smoking may affect graft survival.

As of 1994, treatments for liver cancer had not significantly improved patient survival.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.

Palliative chemotherapy is cost-effective for advanced gastric and colorectal cancer but not clearly for pancreatic-biliary cancer.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.

Nab-paclitaxel is as effective as cisplatin but safer for early-stage cervical cancer treatment.